English
Español
CONTACT US
HOME

ONCOMATRYX

pioneering stromal medicine

Month: March 2022

Oncomatryx Capital increase 2022

Published by EXPANSIÓN 2022-03-08 Oncomatryx has carried out a capital increase of 15 million euros to start clinical trials with people with invasive tumors in Spain and the USA.

OMTX2022-03-092022-03-15 PRESS Releases No Comments Read more

Bizkaia Impacto Social 2022 Award

Published by El Correo 2022-03-07. Oncomatryx Biopharma, S.L. has been honoured with the 2022 Bizkaia Social Impact Award (Premio Impacto Social 2022) by BBK and EL CORREO at the Sustainable Competitiveness Awards

OMTX2022-03-072022-03-09 PRESS Releases No Comments Read more

Meta

UE Next Generation

This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.

PRECISION DRUGS

PRECISION DRUGS
ANTIBODY DRUG CONJUGATES
PIPELINE

DIAGNOSTICS

COL11A1 BIOMARKER
INVASIVE TUMOR DIAGNOSTICS -invaScan-
BLADDER CANCER DIAGNOSTICS -bladderScan-

With the collaboration of:

English
Español
TERMS OF USE
PRIVACY POLICY
SITE MAP

By continuing to use the site, you agree to the use of cookies. Continue, scroll or accept. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.